Long Term Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine 1437173A and Assessment of Re-vaccination With 2 Additional Doses, in Healthy Subjects Aged 60 Years of Age and Older

Trial Profile

Long Term Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine 1437173A and Assessment of Re-vaccination With 2 Additional Doses, in Healthy Subjects Aged 60 Years of Age and Older

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics
  • Acronyms ZOSTER-060 EXT:003
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 25 May 2017 Planned End Date changed from 7 Dec 2018 to 15 Nov 2018.
    • 10 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Aug 2017.
    • 26 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top